Search results
Results from the WOW.Com Content Network
Lupus nephritis commonly leads patients to chronic kidney failure and therefore places an emphasis on early intervention for improving treatment outcomes. It is a significant risk factor for morbidity and mortality in systemic lupus erythematosus. The management of lupus nephritis comprises immunosuppressive therapy to lessen inflammation and ...
Ianalumab (INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus. [2] [3] [4] This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials.
Belimumab was not effective in Phase II clinical trials for rheumatoid arthritis. [30] It was moderately effective in Phase II trials for Sjögren syndrome. [31] In December 2020, belimumab was approved by the FDA as a treatment for lupus nephritis in combination with standard treatment. [32]
Idera Announces Initiation of Lupus Clinical Development Program with Phase 1 Trial of IMO-8400 Presents IMO-8400 Preclinical Data Supporting Autoimmune Activity at ACR/AHRP 2012 CAMBRIDGE, Mass ...
Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. [1] Symptoms of these diseases can affect many different body systems, including joints , skin , kidneys , blood cells , heart , and lungs .
A breakthrough was made in 1948 with the discovery of the LE cell (the lupus erythematosus cell—a misnomer, as it occurs with other diseases as well). Discovered by a team of researchers at the Mayo Clinic, they discovered that the white blood cells contained the nucleus of another cell that was pushing against the white's cell proper nucleus.
Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug ...
Nephritic syndrome is a syndrome comprising signs of nephritis, which is kidney disease involving inflammation. It often occurs in the glomerulus , where it is called glomerulonephritis . Glomerulonephritis is characterized by inflammation and thinning of the glomerular basement membrane and the occurrence of small pores in the podocytes of the ...